Versatile polyurethane materials from Bayer provide the right prescription for modern wound treatment, medical packaging

NEW YORK, June 10, 2014 /PRNewswire/ -- Bayer MaterialScience offers a wide range of thermoplastic polyurethane films and polyurethane-based adhesives and foams formulated to meet the rigorous requirements of today's medical device and healthcare markets. For OEMs looking for innovative materials to bring their latest products to market, you could say the solutions offered by Bayer are "just what the doctor ordered."

The company will highlight its materials for this market at MD&M East 2014 – the East Coast's largest medical technology event. Here's a preview.

Bayfol^® UX502 multilayer medical packaging film is designed and manufactured to meet the demanding requirements to protect sensitive medical devices like orthopedic implants. Bayfol^® UX502 film combines the ease of thermoforming processability with high abrasion resistance to help resist material wear issues associated with standard medical packaging. Multiple films of different materials are no longer needed to obtain these attributes as Bayfol^® UX502 film does it all, providing superior protection while delivering thermoforming capability and inventory cost savings.

Platilon^® and Dureflex^® films: Wound dressings made with these films help protect wounds from environmental influences and accelerate the healing process with their high breathability. The films feel like a second skin for the patient's comfort and may also be used to make surgical drapes that are skin-friendly and conform to the patient's body shape. Surgeons value the customized surfaces and excellent adhesion for easy peel-off after surgery. Platilon^® and Dureflex^® films can also be fabricated to make medical bladders for air or liquid retention.

Bayer will demonstrate its polyurethane gentle skin adhesive made from Baymedix^® A. The material's adjustable adhesive strength offers an excellent solution for a wide range of wound care and skin contact applications. Additionally, the adhesive provides the advantages of breathability and compatibility with common device sterilization technologies.

When combined with Bayer's breathable TPU films, OEM's can achieve excellent breathability without perforation, thereby minimizing processing costs.

Bayer will also highlight breathable, soft touch films made from Baymedix^® FD waterborne dispersions at MD&M East. When the waterborne polyurethane dispersions are combined with the new Baymedix^® FP520 cross-linker, these films display high chemical stability in the presence of disinfectants. This feature is valuable for wound care and protective coverings.

Baymedix^® FP reactive foam technology enables the production of very smooth and conformable foams that are non-yellowing, have high absorption rates and great fluid retention capability.

Attendees at MD&M East Conference and Exposition, June 10-12 in New York City, can visit Bayer's booth (#556) for more details about Bayer's material solutions for medical applications.

About Bayer MaterialScience LLC:
Bayer MaterialScience LLC is one of the leading producers of high-performance plastics in North America and is part of the global Bayer MaterialScience business with approximately 14,300 employees at 30 production sites around the world and 2013 sales of 11.2 billion euros. Bayer MaterialScience, a Bayer Group company, manufactures high-tech polymer materials and develops innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction, medical, and sports and leisure industries. Sustainability is central to Bayer MaterialScience LLC's business and is based around the key areas of innovation, product stewardship, social responsibility and respect for the environment.

For more information about Bayer MaterialScience's complete range of polyurethane materials for modern wound treatment, visit www.baymedix.com.

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Editor's Note: Follow news from Bayer MaterialScience on Twitter: www.twitter.com/Bayer4materials.

SOURCE Bayer MaterialScience LLC